Alnylam Ranks #1 on Boston Globe’s Top Places to Work List for 2023
30 Novembro 2023 - 10:00AM
Business Wire
– Recognition Marks Alnylam’s Ninth Year in a
Row on this Prestigious List, and the Third Consecutive Year
Ranking #1 –
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi
therapeutics company, announced its first-place ranking in Boston
Globe’s 2023 Top Places to Work in the “Largest Employer” category.
This marks the third year in a row that Alnylam has taken the top
spot in the Largest Employer category (> 1,000 employees).
“We strive to set the gold standard for workplace excellence
with our science, our people, and our culture. We are proud to be
recognized as the #1 Top Place to Work by The Boston Globe for the
third year in a row,” said Kelley Boucher, Chief Human Resources
Officer of Alnylam. “We are committed to providing an amazing
experience for our employees who bring their best every day in
order to provide life-changing RNAi medicines to patients who can
benefit from them. It’s simply in our RNA!”
Companies named to the Top Places to Work list are chosen by the
people who best understand the workplace environment: the
employees. Employees complete an anonymous, research-backed survey
assessing categories, including their company’s direction,
execution, connection, management, work, pay and benefits, and
engagement. The list spotlights companies that support employees
both in and out of the office, including caregiving, mental health,
and other out-of-office needs.
The Top Places to Work survey is completed by 137,000 employees
across 347 different companies in Massachusetts. The winners are
constantly working to improve their workplaces, from investigating
how artificial intelligence can assist workers, not replace them,
to helping workers get to know each other in an increasingly hybrid
world. This honor comes shortly after Alnylam ranked in the top
three in Science Magazine’s 2023 Top Employer Survey.
About Alnylam Pharmaceuticals Alnylam Pharmaceuticals
(Nasdaq: ALNY) has led the translation of RNA interference (RNAi)
into a whole new class of innovative medicines with the potential
to transform the lives of people afflicted with rare and prevalent
diseases with unmet need. Based on Nobel Prize-winning science,
RNAi therapeutics represent a powerful, clinically validated
approach yielding transformative medicines. Since its founding in
2002, Alnylam has led the RNAi Revolution and continues to deliver
on a bold vision to turn scientific possibility into reality.
Alnylam’s commercial RNAi therapeutic products are ONPATTRO®
(patisiran), AMVUTTRA® (vutrisiran), GIVLAARI® (givosiran), OXLUMO®
(lumasiran), and Leqvio® (inclisiran), which is being developed and
commercialized by Alnylam’s partner, Novartis. Alnylam has a deep
pipeline of investigational medicines, including multiple product
candidates that are in late-stage development. Alnylam is executing
on its “Alnylam P5x25” strategy to deliver transformative medicines
in both rare and common diseases benefiting patients around the
world through sustainable innovation and exceptional financial
performance, resulting in a leading biotech profile. Alnylam is
headquartered in Cambridge, MA. For more information about our
people, science and pipeline, please visit www.alnylam.com and
engage with us on X (formerly Twitter) at @Alnylam, on LinkedIn, or
on Instagram.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20231130987077/en/
Alnylam Pharmaceuticals, Inc.
Christine Regan Lindenboom (Investors and Media)
+1-617-682-4340
Josh Brodsky (Investors) +1-617-551-8276
Alnylam Pharmaceuticals (NASDAQ:ALNY)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Alnylam Pharmaceuticals (NASDAQ:ALNY)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024